Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
QURE Stock Forecast 2025-2026
$12.79
Current Price
$699.98M
Market Cap
Buy 11
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to QURE Price Targets
+446.1%
To High Target of $69.84
+134.2%
To Median Target of $29.96
+1.0%
To Low Target of $12.91
QURE Price Momentum
-19.5%
1 Week Change
+43.2%
1 Month Change
+160.0%
1 Year Change
-27.6%
Year-to-Date Change
-33.3%
From 52W High of $19.18
+242.9%
From 52W Low of $3.73
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching uniQure (QURE) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on QURE and similar high-potential opportunities.
Latest QURE Stock Price Targets & Analyst Predictions
Based on our analysis of 21 Wall Street analysts, QURE has a bullish consensus with a median price target of $29.96 (ranging from $12.91 to $69.84). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $12.79, the median forecast implies a 134.2% upside. This outlook is supported by 11 Buy, 2 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
QURE Analyst Ratings
11
Buy
2
Hold
0
Sell
QURE Price Target Range
Low
$12.91
Average
$29.96
High
$69.84
Current: $12.79
Latest QURE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for QURE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 6, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $38.00 |
| Apr 21, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $70.00 |
| Apr 1, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $38.00 |
| Mar 4, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $70.00 |
| Feb 28, 2025 | Wells Fargo | Yanan Zhu | Equal-Weight | Maintains | $30.00 |
| Jan 27, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $70.00 |
| Jan 21, 2025 | RBC Capital | Luca Issi | Outperform | Reiterates | $24.00 |
| Dec 19, 2024 | Mizuho | Uy Ear | Neutral | Maintains | $20.00 |
| Dec 16, 2024 | Stifel | Paul Matteis | Buy | Maintains | $32.00 |
| Dec 12, 2024 | Goldman Sachs | Salveen Richter | Neutral | Maintains | $20.00 |
| Dec 11, 2024 | Guggenheim | Debjit Chattopadhyay | Buy | Reiterates | $0.00 |
| Dec 11, 2024 | Leerink Partners | Outperform | Maintains | $44.00 | |
| Dec 11, 2024 | RBC Capital | Luca Issi | Outperform | Maintains | $20.00 |
| Dec 10, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Maintains | $58.00 |
| Dec 10, 2024 | Raymond James | Danielle Brill | Strong Buy | Upgrade | $52.00 |
| Dec 10, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $25.00 |
| Nov 6, 2024 | RBC Capital | Luca Issi | Outperform | Maintains | $14.00 |
| Nov 6, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $28.00 |
| Nov 6, 2024 | Goldman Sachs | Salveen Richter | Neutral | Maintains | $9.00 |
| Nov 6, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $25.00 |
Uniqure N.V. (QURE) Competitors
The following stocks are similar to uniQure based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Uniqure N.V. (QURE) Financial Data
Uniqure N.V. has a market capitalization of $699.98M with a P/E ratio of -2.6x. The company generates $27.12M in trailing twelve-month revenue with a 32.4% profit margin.
Revenue growth is -21.9% quarter-over-quarter, while maintaining an operating margin of -796.3% and return on equity of -238.5%.
Valuation Metrics
Market Cap
$699.98M
Enterprise Value
$795.91M
P/E Ratio
-2.6x
PEG Ratio
-4.2x
Price/Sales
25.8x
Growth & Margins
Revenue Growth (YoY)
-21.9%
Gross Margin
+88.1%
Operating Margin
-796.3%
Net Margin
+32.4%
EPS Growth
-21.9%
Financial Health
Cash/Price Ratio
+53.1%
Current Ratio
9.7x
Debt/Equity
-74.2x
ROE
-238.5%
ROA
-16.4%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Uniqure N.V. (QURE) Business Model
About Uniqure N.V.
What They Do
Develops transformative gene therapies for rare diseases.
Business Model
Uniqure N.V. generates revenue through the development and commercialization of innovative gene therapies focused on treating genetic disorders. Utilizing its proprietary gene therapy platform, the company aims to provide durable therapeutic effects, primarily targeting conditions like hemophilia B and Huntington’s disease.
Additional Information
Based in the Netherlands with facilities in the U.S., Uniqure is positioned in the healthcare and biotechnology sectors, emphasizing innovative treatment solutions. The company's progress in clinical trials can significantly impact market sentiment and investment trends in the biotech industry, representing a strong potential for improving patient outcomes globally.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
480
CEO
Mr. Matthew Craig Kapusta CPA
Country
Netherlands
IPO Year
2014
Website
www.uniqure.comUniqure N.V. (QURE) Latest News & Analysis
Latest News
Quick Summary
uniQure N.V. (NASDAQ:QURE) will hold its Q1 2025 earnings conference call on May 9, 2025, at 8:30 AM ET, featuring key executives and analysts from various firms.
Why It Matters
The earnings call will provide insights into uniQure's financial performance and strategic direction, influencing investor sentiment and stock price movements.
Source: Seeking Alpha
Market Sentiment:
Neutral
uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress
2 days ago
Quick Summary
AMT-130 received FDA Breakthrough Therapy designation; early safety data shows it is well-tolerated. Cash reserves of $409M expected to fund operations into 2027. Regulatory updates due in Q2 2025.
Why It Matters
The FDA's Breakthrough Therapy designation for AMT-130 signals potential faster regulatory approval, while positive safety data and ample funding enhance investor confidence in uniQure's pipeline and future prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
UniQure (QURE) reported a quarterly loss of $0.82 per share, better than the estimated loss of $1.07, and improved from a loss of $1.36 per share a year prior.
Why It Matters
UniQure's smaller-than-expected quarterly loss signals improving financial health, potentially boosting investor confidence and affecting stock performance positively.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
uniQure plans to apply for accelerated approval for its Huntington's Disease program. PTC Therapeutics reported positive phase 2 trial results for its Huntington's treatment.
Why It Matters
uniQure's accelerated approval pathway signals potential rapid market entry, while PTC's positive trial results boost optimism in Huntington's Disease treatments, impacting stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
uniQure will hold its inaugural earnings call on May 9, 2025, at 8:30 a.m. ET.
Why It Matters
uniQure's inaugural earnings call signals increased transparency and potential growth, providing insights into financial health and strategic direction, impacting investor confidence and stock valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
uniQure (QURE) experienced significant trading volume recently, but earnings estimate revisions suggest potential challenges for continued upward movement in the stock.
Why It Matters
Increased trading volume signals heightened interest in uniQure, but negative earnings estimate revisions suggest potential stock weakness ahead, impacting investor sentiment and decisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About QURE Stock
What is Uniqure N.V.'s (QURE) stock forecast for 2025?
Based on our analysis of 21 Wall Street analysts, Uniqure N.V. (QURE) has a median price target of $29.96. The highest price target is $69.84 and the lowest is $12.91.
Is QURE stock a good investment in 2025?
According to current analyst ratings, QURE has 11 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $12.79. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for QURE stock?
Wall Street analysts predict QURE stock could reach $29.96 in the next 12 months. This represents a 134.2% increase from the current price of $12.79. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Uniqure N.V.'s business model?
Uniqure N.V. generates revenue through the development and commercialization of innovative gene therapies focused on treating genetic disorders. Utilizing its proprietary gene therapy platform, the company aims to provide durable therapeutic effects, primarily targeting conditions like hemophilia B and Huntington’s disease.
What is the highest forecasted price for QURE Uniqure N.V.?
The highest price target for QURE is $69.84 from at , which represents a 446.1% increase from the current price of $12.79.
What is the lowest forecasted price for QURE Uniqure N.V.?
The lowest price target for QURE is $12.91 from at , which represents a 1.0% increase from the current price of $12.79.
What is the overall QURE consensus from analysts for Uniqure N.V.?
The overall analyst consensus for QURE is bullish. Out of 21 Wall Street analysts, 11 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $29.96.
How accurate are QURE stock price projections?
Stock price projections, including those for Uniqure N.V., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 11, 2025 5:01 PM UTC